Evidence for the Treatment of Osteoporosis with Vitamin D in Residential Care and in the Community Dwelling Elderly

Table 6

Effect of vitamin D on bone turnover markers.

	Sample size	Time	Regimen	25(OH)D (nmol/L^¶)		PTH (pmol/L)		ALP (U/L)
				Baseline	Followup	Baseline	Followup	Baseline	Followup
Chapuy	142	18 months	CaD; P	40±28; 33±23	105±23 *; 28±18	5.9±4.1; 5.5±2.6	3.3±1.5 *; 6.2±3.2^§	69±25; 72±25	67±22; 89±27^§
Decalyos II	583	2 years	CaD fixed; CaD split; P	21±13; 23±17; 23±17	↑^#; ↑^#; NR	7.8±8.4; 7.8±5.6; 7.9±5.3	↓^#; ↓^#; ↑	NA; NA; NA	NA; NA; NA
RECORD	60	1 year	CaD; D; P	Combined; 38±16	+24±17; +24±22; +8±18	Combined; 5.5±2.4	−1.9±2.2; −0.7±1.6; −0.7±1.5	NA; NA; NA	NA; NA; NA
Zhu	302	1 year	CaD; Ca	45±13; 44±13	+34%*; NA	7.8±3.0; 7.9±3.1	−3.7±2.6%; −2.8±2.5%	NA; NA	NA; NA
Kyphos sub-study	120	5 years	CaD; Ca; P	70±26; 67±26; 67±34	106±29^#§; 64±29; 62±34	3.7±1.3; 3.9±1.7; 3.9±1.2	NA; NA; NA	80±21; 84±18; 83±18	↓^‡; NA; NA
Heikinheimo; residential	33	Final treatment + 1 year	D; P	NA; NA	45±16; 14±5	NA; NA	NA; NA	NR; NR	NR; NR
Heikinheimo; community	29	Final treatment + 1 year	D; P	NA; NA	49±14; 31±14	NA; NA	NA; NA	NR; NR	NR; NR
Lips	96	3 years	D; P	NA; NA	54; (43–61)^#; 23; (17–28)	NA; NA	NA; NA	NA; NA	NA; NA
Ooms	270	1 year	D; P	27; (19–36); 26; (19–37)	62; (52–70)^#; 23; (17–31)	3.3; (2.4–4.6); 3.5; (2.7–5.0)	3.1; (2.3–4.1)^‡; 3.7; (2.5–5.8)	63; (53–78); 66; (55–78)	62; (53–74); 66; (54–76)
Meyer	70	1 year	D; P	47±26; 51±33	64±21^#; 46±20	6.5±3.1; 5.6±3.3	7.5±4.2; 7.2±4.7	NA; NA	NA; NA
Lyons	102	At least 5 doses	D; P	NA; NA	80.1^𝛿; 54.0	NA; NA	5.0^𝛾; 6.65	NA; NA	NA; NA
Smith	43	4/12	D; P	Combined; 141±59	+21%; NA	4.8 (3.9–5.6)	−17%; NA	NA; NA	NA; NA

Ca: calcium; D: vitamin D; P: placebo; NA: not available; NR: not recorded; ↓: decreased; ↑: increased.
Plus-minus values: means ± SD. Values followed parentheses: median (interquartile range). Results nonsignificant unless indicated.  ¶To convert to ng/mL divide by 2.5.  *𝑃≤0.005 compared to baseline.  ^§𝑃≤0.05 compared to baseline.  ^#𝑃≤0.005 compared to placebo.  ^‡𝑃≤0.05 compared to placebo.  𝛿Difference between means 10.4 ng/mL (95% CI: 6.6–14.2).  𝛾Difference between means 1.65 pmol/L (95% CI: 0.54–2.74).